ClinicalTrials.gg
CompletedNCT05660200Updated Jan 11, 2023

Cross-over Study to Evaluate the Rate and the Extent of Iron Absorption of an ODF Iron Supplement vs an Iron Supplement in Capsules

An interventional study of IBSA Iron ODF and SiderAL® FORTE in Iron-deficiency, sponsored by IBSA Farmaceutici Italia Srl. Completed at 1 site in Italy. Open to female participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-11.

Sponsored by IBSA Farmaceutici Italia Srl (part of IBSA Institut Biochimique SA) · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 15 studies in Anemia, Iron-Deficiency with a site in Italy — 3 open to participants now, 3 under way, none of them phase 3. Anemia, Iron-Deficiency · Italy.

Enrollment
12th of 12
9 · median 152
Started
2022
the only one that year
No phase
5 of 15
1 open now
Registered
11th of 15
by date
Lead sponsor
2 of 15
IBSA Farmaceutici Italia Srl

Among the 15 studies in Anemia, Iron-Deficiency with a site in Italy, this one is the 12th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2022, is one of 5 with no phase, and was the 11th registered.

Anemia, Iron-Deficiency

602 studies on the registry are indexed under Anemia, Iron-Deficiency; 93 are open to participants now.

Browse Anemia, Iron-Deficiency studies →

Open to participants now

3 of the 15 studies in Anemia, Iron-Deficiency with a site in Italy are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 53 Anemia, Iron-Deficiency studies recruiting now, 19 (36%) set no upper age limit and 30 (57%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 55 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Anemia, Iron-Deficiency with a site in Italy, or all of them as a file.
02

Study summary

Open, monocentric, comparative, cross-over study to evaluate the rate and the extent of iron absorption after a single oral dose of (A) IBSA Iron orodispersible film vs (B) SiderAL® FORTE capsules in healthy women aged 18 to 55 years.

Read the detailed description

Open, monocentric, comparative cross-over study to compare the rate and the extent of iron absorption after a single oral dose of (A) IBSA Iron orodispersible film vs (B) SiderAL® FORTE capsules in healthy women aged 18 to 55 years.

IBSA Iron is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film.

SiderAL® FORTE is a preparation based on ferric pyrophosphate and Vit.C in capsules.

Each subject will be observed for two consecutive days (phase I, day -1 and day 0) and after a 7-day washout (phase II) for an additional two consecutive days (day -1 and day 0). Half of the enrolled subjects will take A in phase I and B in phase II; the remaining half of the enrolled subjects will take B in phase I and A in phase II.

In the two days (day -1 and day 0) of both phases, peripheral blood samples will be taken and the defined parameters, indicative of blood iron levels, will be measured.

The primary endpoint is the AUC0-t, Tmax and Cmax of serum iron. The secondary endpoints are the standard parameters indicative of blood iron levels.

03

Conditions studied

  • Iron-deficiency
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written signed prior to inclusion in the study;
  • Women 18-55 years;
  • Ability to understand the nature and the purpose of the study, including possible risks and side effects;
  • Cability to collaborate with the investigator and meet the requirements of the entire study

Exclusion criteria

Exclusion Criteria:

  • Smoke
  • abnormalities in the evaluation
  • Clinically significant abnormal laboratory values indicative of disease
  • Known allergy or presumed to the food supplement investigated (iron) and / or to the of the two formulations;
  • History of anaphylaxis from drugs, dietary supplements or allergic reactions in general, which the investigator believed could influence the outcome of the study
  • Significant history of kidney, liver, gastrointestinal, cardiovascular, respiratory, skin, haematological, endocrine or neurological diseases that may interfere with the purpose of the study
  • Taking herbal remedies and dietary supplements in the 2 weeks prior to the start of the study
  • Taking , thyroid hormones, antibiotics, antiepileptics
  • Alcohol abuse
  • Any clinical condition that in the investigator's judgment is deemed incompatible with study participation
  • Women who are pregnant or breastfeeding
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    IBSA Iron ODF

    A single dose of IBSA Iron ODF containing 30mg Iron and 400ug folic acid will be admistered to healthy female volounteers in one of the two consecutive study periods with a 7-day washout interval between the two administrations.

    Dietary Supplement: IBSA Iron ODF

  • Active comparator
    SiderAL® FORTE

    A single dose of SiderAL® FORTE containing 30mg Iron and 70mg vitamin C will be admistered to healthy female volounteers in one of the two consecutive study periods with a 7-day washout interval between the two administrations.

    Dietary Supplement: SiderAL® FORTE

Interventions

  • Dietary supplementIBSA Iron ODF

    IBSA Iron ODF is a food supplement based on ferric pyrophosphate and folic acid in orodispersible film. IBSA Iron ODF appears as a yellow, opaque, homogeneous film, without visible particles. Once taken, it dissolves on the tongue and can be swallowed without adding water.

  • Dietary supplementSucrosomial ironStudies of Sucrosomial ironSucrosomial iron pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Sideral® r.m. contained in SiderAL® FORTE is an iron protected with Sucrosomial® Technology which passes through the gastric environment intact and is absorbed in the intestine, thus preventing any irritation and discomfort to the stomach. The presence of Vitamin C facilitates the absorption of iron.

    Also known as: Sucrosomial iron

06

What researchers measure

Primary outcomes

  1. Maximum plasma concentration of serum Iron

    Maximum plasma concentration (Cmax) of serum iron to evaluate the rate of absorption of iron after a single oral dose of test versus reference

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

  2. Tmax of serum iron

    Time to achieve Cmax (Tmax) after a single oral dose of test versus reference

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

  3. AUC0-8 of serum iron

    Evaluation of area under the curve of serum iron up to 8h post-administration to evaluate the extent of iron absorption after a single oral dose of test versus reference

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

Secondary outcomes

  1. Change from baseline in blood concentration of hemoglobin

    Evalution of the change from baseline of hemoglobin after administration of test versus reference product

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

  2. Change from baseline in blood concentration of hematocrit

    Evalution of the change from baseline of hematocrit after administration of test versus reference product

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

  3. Change from baseline in blood concentration of ferritin

    Evalution of the change from baseline of ferritin after administration of test versus reference product

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

  4. Change from baseline in blood concentration of transferrin

    Evalution of the change from baseline of transferrin after administration of test versus reference product

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

  5. Change from baseline in blood concentration of transferrin receptor

    Evalution of the change from baseline of transferrin receptor after administration of test versus reference product

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

  6. Change from baseline in blood concentration of folic acid

    Evalution of the change from baseline of folic acid after administration of test versus reference product

    Time frame: -24 hour, 0 hour, 1 hour, 2 hour, 3 hour, 4 hour, 5 hour, 8 hour

07

Study locations

1 site
  • Fondazione Policlinico Universitario Campus Bio-Medico di Roma
    Roma, 00128, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Dec 2022, 0 months.

Of 142 interventional studies with no phase under Anemia, Iron-Deficiency, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's 0 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Dec 21, 2022
StartActual
Nov 25, 2022
Primary completionActual
Dec 3, 2022
CompletionActual
Dec 31, 2022
Last update
Jan 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05660200
Collaborators
Informapro Srl
Responsible party
Sponsor
First posted
Dec 21, 2022
Start date
Nov 25, 2022
Primary completion
Dec 3, 2022
Completion
Dec 31, 2022
Last update
Jan 11, 2023

Study contacts

Silvia Angeletti
principal investigator · Operative Research Unit of Clinical Laboratory

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion